Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753272 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 43,695
- Enrollment target
NCT00753272: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00753272 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 43,695 participants, above the 769-participant average among 15,282 other Phase 3 trials with a reported enrollment target (5582% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00753272, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 43,695 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older. The study design is divided in two surveillance phases: one passive phase along the study during the influenza season and one active surveillance phase during the influenza peak season.
Primary Outcome
Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.
Interventions
- BIOLOGICAL GSK Bio's influenza vaccine GSK2186877A
- BIOLOGICAL Fluarix TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43,695 participants |
| Start Date | 2008-09-15 |
| Est. Completion | 2011-01-05 |
| Phase | Phase 3 |
What the finished NCT00753272 record still lists
NCT00753272 is an interventional study that assigns participants to a tested intervention. Its 43,695 participants enrollment target places it among the larger protocols in the corpus, above the 769-participant average among 15,282 other Phase 3 trials with a reported enrollment target (5582% higher).
The record links to 0 conditions, and to 2 interventions - of which GSK Bio's influenza vaccine GSK2186877A is the first listed.
NCT00753272 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00753272 about?
NCT00753272 is a clinical study titled "Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older". The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older. The study design is divided in two surveillance phases: one passive phase along the study during the influenza season and one active surveillance ph...
What is the current status of trial NCT00753272?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 43,695 participants. The study started on 2008-09-15. Estimated completion is 2011-01-05.
What interventions are being tested in trial NCT00753272?
The interventions under investigation include: GSK Bio's influenza vaccine GSK2186877A (BIOLOGICAL), Fluarix TM (BIOLOGICAL).
Who is sponsoring clinical trial NCT00753272?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00753272's enrollment target sits among peer trials
43,695 3rd of 2000 higher than 1,998 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05607732 · 45,257 participants · NA
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
- NCT06824350 · 45,450 participants · NA
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
- NCT06597968 · 45,991 participants
Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI